Canada markets closed

Grifols, S.A. (GIFLF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
9.410.00 (0.00%)
At close: 03:58PM EDT
Full screen
Loading interactive chart...
  • GlobeNewswire

    GigaGen Awarded Contract by U.S. Department of Defense to Discover Synthetic Human Antibody Treatments for High-Priority Toxins and Pathogens

    SOUTH SAN FRANCISCO, Calif., Sept. 15, 2022 (GLOBE NEWSWIRE) -- GigaGen Inc., a biotechnology company advancing transformative antibody drugs for immune deficiencies, infectious diseases and checkpoint resistant cancers, and a subsidiary of Grifols, announced today it has entered into a contract with the U.S. Department of Defense’s (DOD) Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) to demonstrate the utility of its first-in-class recombi

  • CNW Group

    Grifols enters into agreement with Canadian Blood Services to accelerate self-sufficiency in immunoglobulins for Canada

    Grifols (MCE: GRF) (MCE: GRF.P) (NASDAQ: GRFS), a global leader in plasma medicines with more than 110 years contributing to improve the health and well-being of people, today announced it has signed a pioneering long-term agreement with Canadian Blood Services, Canada's national blood authority, to greatly increase the country's self-sufficiency in immunoglobulin (Ig) medicines, essential plasma-protein therapies used to treat a wide range of immunodeficiencies and other medical conditions.

  • Reuters

    Grifols not currently planning capital increase - source

    BARCELONA (Reuters) -Spanish pharmaceuticals company Grifols has no current plans for a capital increase, a company executive told investors on Thursday in response to a news report, a source with knowledge of the matter said. The source said Grifols vice president Nuria Pascual read a statement on behalf of Grifols' chairman, Victor Grifols Roura at an investor day on Thursday, which said: "Regarding the unexpected news published yesterday in Spanish media and replicated by the financial press we want to inform that, for the time being, the board is not analysing any increase in share capital."